Analyst Price Target is $4.75
▲ +10,946.51% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Gamida Cell in the last 3 months. The average price target is $4.75, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 10,946.51% upside from the last price of $0.04.
Current Consensus is
Moderate Buy
The current consensus among 4 investment analysts is to moderate buy stock in Gamida Cell. This Moderate Buy consensus rating has held steady for over two years.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
Read More